Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success?

Literature DB >> 17337677

Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success?

Beth Enderby¹, Iolo Doull.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2007 PMID： 17337677 PMCID： PMC2083400 DOI： 10.1136/adc.2006.094979

Source DB: PubMed Journal: Arch Dis Child ISSN： 0003-9888 Impact factor: 3.791

× No keyword cloud information.

25 in total

1. Defining a pulmonary exacerbation in cystic fibrosis.

Authors: M Rosenfeld; J Emerson; J Williams-Warren; M Pepe; A Smith; A B Montgomery; B Ramsey
Journal: J Pediatr Date: 2001-09 Impact factor: 4.406

2. Variability of pulmonary function tests in cystic fibrosis.

Authors: P J Cooper; C F Robertson; I L Hudson; P D Phelan
Journal: Pediatr Pulmonol Date: 1990

3. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.

Authors: A Clement; A Tamalet; E Leroux; S Ravilly; B Fauroux; J-P Jais
Journal: Thorax Date: 2006-06-29 Impact factor: 9.139

4. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.

Authors: J M Quan; H A Tiddens; J P Sy; S G McKenzie; M D Montgomery; P J Robinson; M E Wohl; M W Konstan
Journal: J Pediatr Date: 2001-12 Impact factor: 4.406

5. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.

Authors: Richard B Moss
Journal: Chest Date: 2002-01 Impact factor: 9.410

6. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

Authors: J Wolter; S Seeney; S Bell; S Bowler; P Masel; J McCormack
Journal: Thorax Date: 2002-03 Impact factor: 9.139

7. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Authors: Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell
Journal: JAMA Date: 2003-10-01 Impact factor: 56.272

8. Prediction of mortality in patients with cystic fibrosis.

Authors: E Kerem; J Reisman; M Corey; G J Canny; H Levison
Journal: N Engl J Med Date: 1992-04-30 Impact factor: 91.245

9. Pulmonary exacerbations in cystic fibrosis.

Authors: Harvey R Rabin; Steven M Butler; Mary Ellen B Wohl; David E Geller; Andrew A Colin; Daniel V Schidlow; Charles A Johnson; Michael W Konstan; Warren E Regelmann
Journal: Pediatr Pulmonol Date: 2004-05

10. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis.

Authors: Manfred Ballmann; Horst von der Hardt
Journal: J Cyst Fibros Date: 2002-03 Impact factor: 5.482

5 in total

1. Mode of nitric oxide delivery affects antibacterial action.

Authors: Jackson R Hall; Kaitlyn R Rouillard; Dakota J Suchyta; Micah D Brown; Mona Jasmine R Ahonen; Mark H Schoenfisc
Journal: ACS Biomater Sci Eng Date: 2019-11-13

Review 2. Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function.

Authors: Emer P Reeves; Cormac McCarthy; Oliver J McElvaney; Maya Sakthi N Vijayan; Michelle M White; Danielle M Dunlea; Kerstin Pohl; Noreen Lacey; Noel G McElvaney
Journal: World J Crit Care Med Date: 2015-08-04